Bioextrax AB (SE:BIOEX)

:BIOEX

BIOEX

Bioextrax AB

RESEARCH TOOLSreports

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr121.32M

Enterprise Valuekr101.16M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.05

Next Earnings

May 14, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding46,306,927

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr5.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk and preserves financial optionality. For a loss-making industrial biotech, a debt-free structure extends runway and strategic flexibility, making it easier to pursue partnerships or equity raises without immediate debt service constraints.

Multiple Monetization PathwaysHaving product sales, licensing and contracted R&D as potential revenue channels provides durable business model flexibility. It lets the firm capture value at multiple commercialization stages, diversify revenue timing and partner types, and pivot between fee-based services and scalable IP-led income as tech matures.

Alignment With Structural Industry TailwindsOperating in biorefinery and renewable-bioproducts aligns with longer-term sustainability, circular-economy and regulatory demand trends. Structural support from corporates and regulators for bio-based ingredients and side-stream valorization can widen addressable markets and improve partner economics over multiple years.

Bears Say

Structurally Weak ProfitabilityPersistent negative gross margins and deep operating losses indicate the current cost base is misaligned with revenue scale. Without sustainable gross-profit improvement, the company will struggle to leverage commercial channels or scale licensing, leaving long-term viability dependent on fundamental margin recovery.

Consistent Cash BurnContinuous negative operating and free cash flow, with accelerating burn, forces reliance on external funding. That creates dilution and execution risk, constrains multi-year project investments typical for industrial biotech, and pressures management to prioritize near-term financing over strategic growth initiatives.

Eroding Equity BaseDeclining equity from repeated losses weakens the balance sheet buffer against operational shocks and limits capacity to absorb further write-downs or fund scale-up internally. A shrinking capital base can also reduce bargaining power with partners and make future financing more costly or dilutive.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

2M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr121.32M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 35 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported -kr0.11 earnings per share for the quarter, missing the consensus estimate of kr0 by -kr0.11.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.1.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.11 in its last earnings report, missing expectations of kr0. Following the earnings report the stock price went up 5.98%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.